The new assay will enable drug developers to test new drug candidates for interactions with BCRP, which is involved in drug clearance, resistance of tumors to anticancer drugs, and drug-drug interactions (DDIs).
The company’s cell biologists have over-expressed BCRP in a stable manner in the MDCK cell line, and has created BCRP-MDCK cells, which forms basis of a sensitive test system to screen new drug candidates for inhibition of BCRP.
Absorption Systems chief scientist Ismael Hidalgo said the company is pleased that it is at the point where it can use the new cell line to help customers develop safer, more effective drugs.
"Our various CellPort test systems can provide very definitive data on drug transporters, as required by regulatory agencies such as the FDA," Hidalgo added.